SK284655B6 - Farmaceutický prostriedok vo forme kapsuly alebo lisovanej tablety obsahujúci efavirenz a spôsob jeho výroby - Google Patents

Farmaceutický prostriedok vo forme kapsuly alebo lisovanej tablety obsahujúci efavirenz a spôsob jeho výroby Download PDF

Info

Publication number
SK284655B6
SK284655B6 SK1461-2000A SK14612000A SK284655B6 SK 284655 B6 SK284655 B6 SK 284655B6 SK 14612000 A SK14612000 A SK 14612000A SK 284655 B6 SK284655 B6 SK 284655B6
Authority
SK
Slovakia
Prior art keywords
efavirenz
capsule
starch glycolate
amount
pharmaceutical composition
Prior art date
Application number
SK1461-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK14612000A3 (sk
Inventor
William T. Makooi-Morehead
John D. Buehler
Brian R. Landmann
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22160544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284655(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of SK14612000A3 publication Critical patent/SK14612000A3/sk
Publication of SK284655B6 publication Critical patent/SK284655B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
SK1461-2000A 1998-04-07 1999-04-01 Farmaceutický prostriedok vo forme kapsuly alebo lisovanej tablety obsahujúci efavirenz a spôsob jeho výroby SK284655B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8092598P 1998-04-07 1998-04-07
PCT/US1999/007228 WO1999051239A1 (en) 1998-04-07 1999-04-01 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants

Publications (2)

Publication Number Publication Date
SK14612000A3 SK14612000A3 (sk) 2001-07-10
SK284655B6 true SK284655B6 (sk) 2005-08-04

Family

ID=22160544

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1461-2000A SK284655B6 (sk) 1998-04-07 1999-04-01 Farmaceutický prostriedok vo forme kapsuly alebo lisovanej tablety obsahujúci efavirenz a spôsob jeho výroby

Country Status (27)

Country Link
US (2) US6238695B1 (ru)
EP (1) EP1067936B1 (ru)
JP (1) JP2002510634A (ru)
KR (1) KR100634253B1 (ru)
CN (1) CN1146419C (ru)
AR (1) AR019031A1 (ru)
AT (1) ATE223719T1 (ru)
AU (1) AU756422B2 (ru)
BR (1) BR9908810A (ru)
CA (1) CA2321523C (ru)
CZ (1) CZ300850B6 (ru)
DE (1) DE69902893T2 (ru)
DK (1) DK1067936T3 (ru)
EA (1) EA003217B1 (ru)
EE (1) EE04391B1 (ru)
ES (1) ES2181417T3 (ru)
HU (1) HU228498B1 (ru)
IL (1) IL138078A (ru)
NO (1) NO325824B1 (ru)
NZ (1) NZ507566A (ru)
PL (1) PL194309B1 (ru)
PT (1) PT1067936E (ru)
SK (1) SK284655B6 (ru)
TW (1) TW576741B (ru)
UA (1) UA72207C2 (ru)
WO (1) WO1999051239A1 (ru)
ZA (1) ZA200004313B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (ru) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтическая композиция эфавиренца в сочетании с ингредиентами, обеспечивающими распад таблеток, и способ изготовления быстрорастворимых таблеток и капсул эфавиренца
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
CA2328703C (en) * 1998-06-11 2007-10-30 Pharmacia & Upjohn Company Delavirdine tablet formulation
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US20050053678A1 (en) * 2001-10-03 2005-03-10 Gow Robert T. Methods and compositions for betel nut chewing gum
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
WO2003045327A2 (en) * 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
EP3025718A1 (en) 2003-01-14 2016-06-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2006020962A2 (en) * 2004-08-13 2006-02-23 Gallipot, Inc. Palatable suspending vehicle for pharmaceutical ingredients
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN101272848B (zh) * 2005-07-28 2013-03-13 Isp投资有限公司 改进喷雾干燥的粉末和颗粒材料性质的方法，以及由此生产的产品
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
RU2008128424A (ru) * 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
US20080014228A1 (en) * 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
US20080069876A1 (en) * 2006-09-14 2008-03-20 Moore Ryan G Method for preparing solid dosage forms that form a paste, cream or gel when diluted for final use
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
EP2125938A2 (en) * 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
JP2010536798A (ja) * 2007-08-17 2010-12-02 テバ ファーマシューティカル インダストリーズ リミティド 難溶性薬物の生体利用率を制御するための方法及び組成物
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
AP3551A (en) 2010-01-27 2016-01-18 Viiv Healthcare Co Antiviral therapy
CA2796494A1 (en) * 2010-04-20 2011-10-27 Cipla Limited Pharmaceutical composition
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
CN102872019A (zh) * 2012-09-17 2013-01-16 北京阜康仁生物制药科技有限公司 一种采用微粉化技术的依非韦伦制剂
WO2015059466A1 (en) 2013-10-25 2015-04-30 Cipla Limited Pharmaceutical compositions comprising efavirenz
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
WO2017029225A1 (en) 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880701098A (ko) 1986-04-01 1988-07-25 로버어트 에이 아미테이지 메틸프레드니솔론/소디움 카르복시메틸 전분 정제 조성물
NZ231246A (en) * 1989-04-28 1997-06-24 Daiichi Seiyaku Co Pharmaceutical compositions comprising fluorine containing pyridone-carboxylic acid derivatives
DE69220484T2 (de) * 1992-07-08 1998-02-05 Leiras Oy Augenarzneimittel enthaltend Timolol Hemihydrat
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
UA72207C2 (ru) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтическая композиция эфавиренца в сочетании с ингредиентами, обеспечивающими распад таблеток, и способ изготовления быстрорастворимых таблеток и капсул эфавиренца
PE20000559A1 (es) 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz

Also Published As

Publication number Publication date
CZ300850B6 (cs) 2009-08-26
ZA200004313B (en) 2002-01-30
TW576741B (en) 2004-02-21
US6555133B2 (en) 2003-04-29
EE04391B1 (et) 2004-12-15
AU756422B2 (en) 2003-01-09
PL194309B1 (pl) 2007-05-31
NO20005043D0 (no) 2000-10-06
PL343421A1 (en) 2001-08-13
CN1146419C (zh) 2004-04-21
JP2002510634A (ja) 2002-04-09
CN1296412A (zh) 2001-05-23
NO325824B1 (no) 2008-07-21
UA72207C2 (ru) 2005-02-15
NZ507566A (en) 2002-11-26
EA200001030A1 (ru) 2001-04-23
EE200000589A (et) 2002-04-15
BR9908810A (pt) 2000-12-19
KR20010042473A (ko) 2001-05-25
AR019031A1 (es) 2001-12-26
HUP0101517A3 (en) 2002-11-28
EA003217B1 (ru) 2003-02-27
CA2321523A1 (en) 1999-10-14
ES2181417T3 (es) 2003-02-16
ATE223719T1 (de) 2002-09-15
CZ20003571A3 (cs) 2001-01-17
AU3463799A (en) 1999-10-25
NO20005043L (no) 2000-10-06
US20010012518A1 (en) 2001-08-09
DE69902893D1 (de) 2002-10-17
WO1999051239A1 (en) 1999-10-14
DE69902893T2 (de) 2003-04-30
SK14612000A3 (sk) 2001-07-10
IL138078A (en) 2005-12-18
US6238695B1 (en) 2001-05-29
HUP0101517A2 (hu) 2001-11-28
KR100634253B1 (ko) 2006-10-16
EP1067936B1 (en) 2002-09-11
DK1067936T3 (da) 2003-02-17
IL138078A0 (en) 2001-10-31
PT1067936E (pt) 2002-12-31
EP1067936A1 (en) 2001-01-17
CA2321523C (en) 2008-10-07
HU228498B1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
SK284655B6 (sk) Farmaceutický prostriedok vo forme kapsuly alebo lisovanej tablety obsahujúci efavirenz a spôsob jeho výroby
EP1275391B1 (en) Pharmaceutical compositions containing irbesartan and a diuretic
JP2720932B2 (ja) 経口投与用アセトアミノフエン錠剤の製造法及びアセトアミノフエン二層錠剤
EP1035838B1 (en) Pharmaceutical suspension tablet compositions
US8597666B2 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
AU2017244984A1 (en) Oral preparation having exceptional elutability
EP1266657A1 (en) Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
JP2007308480A (ja) 腸溶性固体分散体を含んでなる固形製剤
CA2563690A1 (en) Pharmaceutical compositions comprising intra- and extra- granular fractions
EA008585B1 (ru) Капсулы флуконазола с улучшенным высвобождением
EP1589957A1 (en) Pharmaceutical compositions and process of production thereof
JPH1121236A (ja) ロキソプロフェン・ナトリウム固形製剤
US20050042279A1 (en) Pharmaceutical formulation comprising more than 15% tamoxifen
RU2682178C2 (ru) Противотуберкулезная стабильная фармацевтическая композиция в форме таблетки с покрытием, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
MXPA00009817A (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
KR100396443B1 (ko) 가용화된 펠로디핀 함유 지속성제제의 조성물 및 그의제조방법
CA2671778A1 (en) Immediate release dosage form of bosentan and process of manufacturing such
WO2010062996A2 (en) Ribavirin composition
WO2004024138A1 (ja) ジオクチルソジウムスルホサクシネート配合固形製剤
NZ561044A (en) Bi-layered modified release tablets for sustained release of guaifenesin combination drugs
CZ2001227A3 (cs) Biologicky zlepšené prostředky obsahující eprosartan v orální pevné dávkové formě

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20190401